GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer

Andras Csejtei, Antax Tibold, Zsuzsa Varga, Katalin Koltai, Agoston Ember, Zsuzsa Orsos, Gergely Feher, Ors Peter Horvath, Istvan Ember, Istvan Kiss

Research output: Article

39 Citations (Scopus)

Abstract

Background: Cancer of the colorectal region is the second most frequent cause of death among malignant diseases. The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on colon cancer was investigated. Patients and Methods: Intraoperatively removed tissue samples were processed from colorectal cancer patients. Cancer-free human samples were used as matched controls. Samples were digested with proteinase-K. DNA solution was used for PCR amplification. Results: No significant difference was found between tumor patients and controls in the investigated polymorphisms. A significant association was found in Dukes' B stage patients between the GSTM1 and p53 gene variants and survival. In patients with GSTM1 null genotype and p53 ArglPro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1 + and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Conclusion: The significance of the investigated polymorphisms in prognosis is dependent on the tumor stage. These parameters might be used in certain cases as prognostic biomarkers in clinical diagnostics and in the planning of individual therapy.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalAnticancer research
Volume28
Issue number3 B
Publication statusPublished - máj. 1 2008

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Csejtei, A., Tibold, A., Varga, Z., Koltai, K., Ember, A., Orsos, Z., Feher, G., Horvath, O. P., Ember, I., & Kiss, I. (2008). GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer research, 28(3 B), 1917-1922.